Details for Patent: 9,447,071

Which drugs does patent 9,447,071 protect, and when does it expire?

Patent 9,447,071 protects OXBRYTA and is included in two NDAs.

This patent has fifty-seven patent family members in twenty-eight countries.

Summary for Patent: 9,447,071

Patent landscape, scope, and claims:

Title:	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Abstract:	Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde (or Compound 1).
Inventor(s):	Li; Zhe (South San Francisco, CA), Parent; Stephan D. (South San Francisco, CA), Houston; Travis (South San Francisco, CA)
Assignee:	Global Blood Therapeutics, Inc. (South San Francisco, CA)
Application Number:	14/616,548
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,447,071

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157-001	Dec 17, 2021		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-002	Oct 14, 2022		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No			Y	Y

International Family Members for US Patent 9,447,071

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	099304
Australia	2015214182
Australia	2020207778